Last updated: July 14, 2026
Executive summary
Taiho Pharmaceutical Co., Ltd. v. Natco Pharma Ltd., No. 1:19-cv-02368 (D.N.J.) is a U.S. Hatch-Waxman patent litigation stemming from Natco’s proposed generic regulatory filing targeting Taiho’s branded product and asserting a design-around via non-infringement and invalidity positions. The case posture indicates a Paragraph IV framework (HWA) with infringement claims directed to at least one of Taiho’s listed patents covering the drug substance, formulation, and/or method-of-use. A litigation summary and outcome (e.g., Markman rulings, summary judgment, settlement terms, and whether Natco launched before expiration) cannot be produced from the information provided: the docket outcome, asserted patents, claim constructions, and any settlement or license dates are not included.
What is the case caption and court for Taiho v. Natco, 1:19-cv-02368?
Answer: United States District Court for the District of New Jersey, case number 1:19-cv-02368, styled Taiho Pharmaceutical Co., Ltd. v. Natco Pharma Ltd.
Core case identifiers
- Court: D.N.J.
- Case number: 1:19-cv-02368
- Parties: Taiho Pharmaceutical Co., Ltd. (plaintiff) vs. Natco Pharma Ltd. (defendant)
Why this matters for IP analysis
A 1:19-cv docket number in D.N.J. with Hatch-Waxman context typically indicates:
- Plaintiff is enforcing Orange Book-listed patents.
- Defendant is likely relying on a Paragraph IV certification framework tied to FDA approval timeline and the 30-month stay.
Which patents were asserted in Taiho v. Natco (1:19-cv-02368)?
Answer: Not determinable from the provided input.
What an asserted-patent list must contain to support an enforcement analysis
A complete litigation analysis requires at minimum:
- Patent numbers (US patents)
- Assignees/owners at filing and at assertion
- Orange Book mapping to drug code and NDA/BLA
- Whether the asserted claims cover:
- drug substance (composition of matter),
- formulation (composition, polymorph, salt, particle size, etc.),
- method of use (labeling-driven infringement),
- manufacturing or process (how the product is made).
Without those specifics, any summary would be incomplete and risk misstating the scope of the estate.
What claims did Taiho allege Natco infringed?
Answer: Not determinable from the provided input.
Claim-scope dimensions that drive case outcomes
In Hatch-Waxman litigations, outcomes turn on:
- Whether infringement is theory-of-the-case based on:
- product identity (composition),
- label-driven use,
- equivalence arguments.
- Whether Taiho asserted independent claims and how dependent claims were construed.
- Whether Natco’s “at-risk” conduct was tied to specific strengths/dosage forms.
What invalidity and non-infringement defenses did Natco raise?
Answer: Not determinable from the provided input.
Standard defenses in Paragraph IV cases that must be tied to docket filings
An accurate defense summary requires docket records for:
- Invalidity: anticipation/obviousness under 35 USC 102/103, indefiniteness, lack of written description/enablement.
- Non-infringement: prosecution history estoppel, claim construction limits, differences in salt/polymorph/formulation, or label carve-outs.
- Procedural defenses: standing, indispensability, venue, or timeliness tied to infringement allegations and stay.
No such filing specifics are included in the request.
What procedural milestones occurred in the Taiho v. Natco docket?
Answer: Not determinable from the provided input.
Milestones that must be confirmed from docket entries
A litigation timeline requires:
- complaint filing date and amended complaints,
- defendants’ answers and counterclaims,
- scheduled Markman date,
- claim construction orders,
- expert reports and Daubert rulings,
- summary judgment motions,
- pretrial orders,
- trial dates or dispositive outcomes,
- any stipulations of dismissal.
Without docket-level events, a timeline would be fabricated.
What did claim construction decide, and how did that affect infringement?
Answer: Not determinable from the provided input.
Why Markman outcomes dominate Hatch-Waxman results
Markman construction often determines:
- whether Natco’s product falls within the literal scope,
- whether the infringement case can survive to trial,
- whether validity is easier to litigate post-construction.
A credible analysis must quote or accurately reference:
- the construed claim limitations,
- the court’s rationale tied to specifications and prosecution history.
No claim construction record is provided.
Did the case end in a settlement, consent judgment, or court decision?
Answer: Not determinable from the provided input.
Settlement analysis requires at least these items from court filings
A proper settlement summary includes:
- whether a license was granted,
- effective date and royalty terms (if disclosed),
- scope restrictions (strengths, dosage forms, markets, manufacturing sites),
- launch/price/market carve-outs,
- whether there was a dismissal with prejudice and under what terms,
- whether any walk-away scenario occurred.
None of those details are included.
What is the FDA and Orange Book regulatory linkage for this litigation?
Answer: Not determinable from the provided input.
Orange Book linkage is required to connect litigation to exclusivity and launch risk
A complete regulatory section must identify:
- the NDA/BLA number and drug product description,
- which patents are listed as relevant to the NDA (and their expiration),
- whether the patents are tied to exclusivity blocks:
- 5-year new chemical entity,
- 3-year new clinical investigation,
- patent term adjustments and restorations,
- pediatric exclusivity.
- whether Natco filed under ANDA and the type of certification:
- Paragraph IV to specific listed patents,
- Paragraph III or I for earlier filing blocks.
The request includes neither the branded product nor the Orange Book listing.
When would generic entry be permitted if Taiho’s patents expired?
Answer: Not determinable from the provided input.
Exclusivity and patent-expiration analysis must use the asserted and Orange Book patents
A credible “when does it lose exclusivity?” analysis depends on:
- patent term end dates for each asserted patent,
- PTA/PTE adjustments (if applicable),
- any terminal disclaimers,
- pediatric exclusivity extensions,
- whether any injunction or settlement delayed market entry.
No patent numbers or expiration dates are provided.
How does this case compare with other Taiho vs. generic company litigations?
Answer: Not determinable from the provided input.
What the comparison must cover
A proper comparison requires:
- asserted patents and claim types across cases,
- common court rulings or judge-specific patterns,
- settlement outcomes and launch timing,
- whether Taiho’s estate is consistently strong or frequently narrowed.
No data about other cases is included.
Commercial and licensing implications for Taiho and Natco
Answer: Not determinable from the provided input.
Commercial analysis requires at least:
- branded annual revenue exposure for Taiho,
- Natco’s ANDA status and approval date,
- anticipated launch date relative to patent expirations,
- whether litigation delayed approval or triggered a design-around,
- whether the settlement includes market-allocation terms.
None of these inputs are included.
Key Takeaways
- The case identification (Taiho Pharmaceutical Co., Ltd. v. Natco Pharma Ltd., No. 1:19-cv-02368, D.N.J.) confirms a U.S. Hatch-Waxman style dispute, but the request does not provide docket facts needed to produce a litigation summary with asserted patents, claim constructions, and outcome.
- Without the asserted-patent list and disposition record, any “litigation summary and analysis” would not meet a professional accuracy standard.
FAQs
- What patents are Orange Book-listed for Taiho’s product that triggered 1:19-cv-02368?
- Which filing type did Natco use in the ANDA for the Taiho v. Natco case (Paragraph IV vs. III or I)?
- Did the court issue any claim construction orders in 1:19-cv-02368, and did they narrow infringement theories?
- Was there a settlement in Taiho v. Natco, and did it include a covenant not to sue or a license?
- What launch-date risk did the litigation create for Natco and other generics in the same therapeutic category?
References
- No citable sources were provided in the prompt, and no specific docket or opinion documents were included.
